- This event has passed.
Topic: Exploring of alternating signaling and its impact on precision therapy in patients with Erdheim-Chester Disease
2:00 PM – 3:00 PM CDT
October 21, 2025 2:00 PM CDT
Date: October 21, 2025
Time: 2:00 PM CT
Speaker: Samuel B. Reynolds, M.D.
Moffitt Cancer Center
Dr. Reynolds is originally from the Boston area and completed medical school at The University of South Florida Morsani College of Medicine. He would then complete an Internal Medicine residency and chief residency at The University of Louisville and a Hematology & Medical Oncology fellowship at The University of Michigan. He began to focus on histiocytic neoplasms in the later part of his training in Ann Arbor. Here, he founded the Michigan Histiocytosis Working Group and has since joined the Histiocytosis Care Network as a researcher and physician.
Throughout his career, Dr. Reynolds has been passionate about the molecular characterization and translational care of hematologic disorders. Under his T32 at The University of Michigan, he would publish several manuscripts pertaining to both outcomes with respect to targeted therapy and trends in peripheral blood monocytosis in histiocytic disorders. He currently serves as an Assistant Professor at the Moffitt Cancer Center and specializes in the research and care of myeloid and histiocytic neoplasms.
The webinar will explore the diversity of Erdheim-Chester Disease (ECD), both among patients and at the genetic level. Because ECD is a rare and complex hematologic cancer, individualized treatment requires a collaborative approach. Understanding each patient’s unique molecular profile—the DNA changes that drive their disease—is key to guiding effective therapy.
